Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
NCT00015847 · OHSU Knight Cancer Institute · PHASE2 · terminated · last registry update 2025-08-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, OHSU Knight Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IFNAR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-07Phase 3 first posted: AstraZeneca, Anifrolumab (NCT07751848)
- 2026-07-31Also stopped (withdrawn): PharmaEssentia, Ropeginterferon alfa-2b (NCT06290765)
- 2026-07-23Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Ruxolitinib (NCT07722611)
- 2026-07-09Phase 3 first posted: AstraZeneca, Anifrolumab + Anifrolumab (NCT07691970)
- 2026-06-18Also stopped (terminated): Centre Hospitalier Universitaire de Nice, Peginterferon Alfa-2A 180 MCG/ML Injectable Solution (NCT05941845)
- 2026-06-03Phase 3 first posted: Incyte Corporation, INCA033989 + Best Available Treatment (NCT07623200)
- 2026-05-20Results posted on the registry: AstraZeneca, Anifrolumab + placebo (NCT04931563)
- 2026-05-19Results posted on the registry: Biogen, dimethyl fumarate + Interferon β-1a (NCT02283853)
- 2026-04-29Results posted on the registry: Arbutus Biopharma Corporation, AB-729 + Peg-IFNα-2a (NCT04980482)
- 2026-04-16Results posted on the registry: Vir Biotechnology, Inc., VIR-2218 + pegylated interferon-alfa 2a (NCT04412863)
- 2026-02-24Phase 3 first posted: AstraZeneca, Anifrolumab (NCT07430306)
- 2026-02-13Also stopped (withdrawn): M.D. Anderson Cancer Center, Paclitaxel + mRNA plus Lysate-loaded Dendritic Cell Vaccine (NCT05799612)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02577029)
- 2025-10-27Results posted on the registry: Mayo Clinic, Ropeginterferon Alfa-2B (NCT02370329)
- 2025-10-27Also stopped (terminated): Mayo Clinic, Ropeginterferon Alfa-2B (NCT02370329)
- 2025-09-19Results posted on the registry: Hoffmann-La Roche, Nucleos(t)ide (NUC) + CpAM (RO7049389) (NCT04225715)
- 2025-09-15Results posted on the registry: PharmaEssentia Japan K.K., P1101 + Low-dose aspirin (NCT04182100)
- 2025-08-24Results posted on the registry: Anna Cruceta, boceprevir + Ribavirin (NCT01718301)
- 2025-08-24Also stopped (terminated): Anna Cruceta, boceprevir + Ribavirin (NCT01718301)
- 2025-06-29Results posted on the registry: Nanogen Pharmaceutical Biotechnology Joint Stock Company, Peginterferon Alfa-2A + Ribavirin Oral Product (NCT06922643)
- 2025-02-06Also stopped (terminated): Bristol-Myers Squibb, BMS-986465 + Pegasys (NCT06144697)
- 2024-12-11Results posted on the registry: M.D. Anderson Cancer Center, IFN-alpha2a (NCT00452023)
- 2024-09-19Results posted on the registry: Janssen Research & Development, LLC, JNJ-73763989 + PegIFN-alpha-2a (NCT04439539)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision